



(12) Translation of
European patent specification

(11) NO/EP 3927337 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/4045 (2006.01)

A61P 25/24 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.06.10
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.02.14
(86)	European Application Nr.	20710059.5
(86)	European Filing Date	2020.02.24
(87)	The European Application's Publication Date	2021.12.29
(30)	Priority	2019.02.22, EP, 19158774
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
	Designated Extension States:	BA; ME
	Designated Validation States:	KH; MA; MD; TN
(73)	Proprietor	GH Research Ireland Limited, Joshua Dawson House Dawson Street, D02 RY95 Dublin 2, Irland
(72)	Inventor	TERWEY, Theis, Christinenstrasse 33, 10119 Berlin, Tyskland
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge

(54)	Title	5-METHOXY-N,N-DIMETHYLTRYPTAMINE (5-MEO-DMT) FOR TREATING MAJOR DEPRESSION
(56)	References Cited:	WO-A1-2018/195455 WO-A1-2019/081764 CARHART-HARRIS R L ET AL: "Psilocybin with psychological support for treatment-resistant depression: six-month follow-up", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 235, no. 2, 8 November 2017 (2017-11-08), pages 399-408, XP036477494, ISSN: 0033-3158, DOI: 10.1007/S00213-017-4771-X [retrieved on 2017-11-08] GEYER M A ET AL: "Behavioural and pharmacological studies of pharmahuasca in rodents", EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 26, 2016, XP029787110, ISSN: 0924-977X, DOI: 10.1016/S0924-977X(16)30889-6 SHEN HONG-WU ET AL: "Nonlinear Pharmacokinetics of 5-Methoxy-N,N-dimethyltryptamine in Mice", DRUG METABOLISM AND DISPOSITION, PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US , vol. 39, no. 7 30 June 2011 (2011-06-30), pages 1227-1234, XP009520579, ISSN: 0090-9556, DOI: 10.1124/DMD.111.039107 Retrieved from the Internet: URL: http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.111.039107 UTHAUG MALIN V ET AL: "Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment", PSYCHOPHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 237, no. 3, 10 December 2019 (2019-12-10), pages 773-785, XP037030419, ISSN: 0033-3158, DOI: 10.1007/S00213-019-05414-W [retrieved on 2019-12-10]

OSÓRIO FDE L ET AL: "Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report", REVISTA BRASILEIRA DE PSIQUIATRIA, PUBL. SOLUTIONS, BR, vol. 37, no. 1, 1 January 2015 (2015-01-01), pages 13-20, XP009520464, ISSN: 1516-4446, DOI: 10.1590/1516-4446-2014-1496

ALAN K. DAVIS ET AL: "5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety", AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, vol. 45, no. 2, 1 March 2019 (2019-03-01), pages 161-169, XP055695498, US ISSN: 0095-2990, DOI: 10.1080/00952990.2018.1545024

THOMAS G ET AL: "Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada", CURRENT DRUG ABUSE REVIEWSE, BENTHAM SCIENCE PUBLISHERS LTD, vol. 6, no. 1, 1 March 2013 (2013-03-01), pages 30-42, XP009520465, ISSN: 1874-4737, DOI: 10.2174/15733998113099990003

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. 5-metoksy-N,N-dimetyltryptamin (5-MeO-DMT) eller et farmasøytisk akseptabelt salt derav for bruk ved behandling av en pasient som er diagnostisert med klinisk depressiv forstyrrelse av en lisensiert fagperson i samsvar med akseptert medisinsk praksis.
2. 5-MeO-DMT eller et farmasøytisk akseptabelt salt derav for bruk ifølge krav 1, hvor forstyrrelsen er diagnostisert i samsvar med Diagnostisk og statistisk håndbok for psykiske lidelser - femte utgave (DSM-5) utgitt av Den amerikanske psykiaterforening.
3. 5-MeO-DMT eller et farmasøytisk akseptabelt salt derav for bruk ifølge kravene 1 eller 2, hvor pasienten lider av moderat eller alvorlig klinisk depressiv forstyrrelse som antydnet av en score på MADRS (Montgomery-Åsberg Depression Rating Scale) på 20 eller mer eller av en score på en 17-delt HAM-D (Hamilton Depression Rating Scale) på 17 eller mer.
4. 5-MeO-DMT eller et farmasøytisk akseptabelt salt derav for bruk ifølge krav 3, hvor pasienten lider av alvorlig klinisk depressiv forstyrrelse som antydnet av en MADRS-score på 35 eller mer eller av en HAM-D-score på 25 eller mer.
5. 5-MeO-DMT eller et farmasøytisk akseptabelt salt derav for bruk ifølge kravene 1 til 4, hvor pasienten er diagnostisert med en behandlingsresistent form for klinisk depressiv forstyrrelse.